Acute heart drugs should be reconsidered for Maori and Pacific Islanders

Researchers at the University of Otago, New Zealand, say standard medication used for acute heart disease should be reconsidered for some Maori and Pacific Island patients because of drug resistance caused by high rates of Group A streptococcal infection, the same infection which leads to rheumatic fever.

The new study recently published in the prestigious British Journal Clinical Pathology confirms research from that with are more likely to have resistance to the standard heart drug streptokinase (SK).

“Many people living in communities with high endemic levels of Group A strep, have been previously infected by Group A streptococcus bacteria and will have antibodies to streptokinase. There’s therefore a real risk that when they have a heart attack and are given this drug it will not work for them,” explains Dr. Garry Nixon from the Department of General Practice and Rural Health in Dunedin.

The study involved 180 patients from the Hokianga, Thames and Central Otago admitted to hospital with a suspected heart attack.

“It’s clear from our results that patients in the Hokianga, the rural community with the highest proportion of Maori and lowest socio-economic status, have resistance to streptokinase medication which is 2.8 times higher than in Central Otago, with the lowest proportion of Maori and higher socio-economic status.”

Dr. Nixon says these very significant differences mean that newer fibrinolytic heart drugs should be used for patients with heart attacks in predominantly Maori rural communities. However, he says these fibrinolytic agents which are not affected by the immune system, are more expensive than SK drugs, affecting their uptake.

This new research provides strong support for the recent moves away from SK as a standard treatment for heart attacks in rural New Zealand, particularly in predominantly Maori communities.

“Perhaps most importantly this is a timely reminder of the need to exercise caution when translating the results of drug trials carried out on Caucasians to other ethnic groups such and Maori and Pacific Islanders. This is particularly important when a mechanism of , such as the one outlined in this study, has been identified.”

Dr. Nixon also points out that similar major health issues remain in the Pacific Islands where there are very high rates of Group A , increasing rates of ischaemic and a continued reliance on streptokinase as a result of limited health budgets.

People living in Samoa, the Cook Islands, French Polynesia and Tonga have some of the highest rates of rheumatic fever in the world. The study also says that Pacific Islanders living in NZ have an incidence of which is even higher than Maori (1.5-2 times).

Provided by University of Otago

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Study recalculates costs of combination vaccines

Apr 17, 2014

One of the most popular vaccine brands for children may not be the most cost-effective choice. And doctors may be overlooking some cost factors when choosing vaccines, driving the market toward what is actually a more expensive ...

Drug watchdog urges vigilance in cancer drug theft

Apr 17, 2014

Europe's medicine watchdog urged doctors Thursday to be vigilant in administering the cancer drug Herceptin, vials of which had been stolen in Italy and tampered with before being sold back into the supply chain.

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

ironjustice
not rated yet May 24, 2011
What significance would there be here that the Pacific Islanders ALSO coincidentally have the "highest blood iron levels of anyone" .. ?
"Asians and Pacific Islanders have the highest mean levels
of iron in their blood of all ethnic groups involved, including African Americans, Caucasians, Hispanics, and Native Americans. Hemochromatosis, one of the most common inherited disorders among Caucasians, can lead to iron overload, or a buildup of iron in the body's organs. This extra iron, which can be easily treated if detected early, can increase the risk of diabetes, arthritis, sexual dysfunction, liver disease and liver cancer and heart disease."